INTERVIEWS

Dr. David Fairchild, MD, MPH, Chief Medical Officer at CVS MinuteClinic discusses the many ways virtual care has evolved since the pandemic’s virtual care boom, based on new data from CVS Health’s Health Care Insights Study.

Dr. Todd Johnson, M.D. is the Chief Growth Officer at M2GEN, an oncology-focused health informatics solutions company with the mission to help patients get access to the best treatments by leveraging clinical and molecular data to accelerate the discovery, development, and delivery of tailored and more personalized therapies. 

Joe Gordon, President, Global Consumer, Surgical and Vision Care at Bausch + Lomb, a leading global eye health company dedicated to protecting and enhancing the gift of sight for millions of people around the world, shares his unique point of view on the industry, Bausch & Lomb’s recent IPO, the upcoming innovation pipeline, and what he’s excited about in this next chapter of the company.  

Dr. Rajeev Jain, MD, FACP, FASGE, AGAF, board-certified gastroenterologist at Texas Digestive Disease Consultants discusses the importance of early treatment for GI symptoms to avoid future complications. In light of the Trust Your Gut campaign, Dr. Jain wants to educate the public and encourage fellow doctors on normalizing the conversation with patients regarding uncomfortable GI symptoms.

Sloane Allebes Phillips, VP of Clinical Operations at Iterative Scopes, discusses the advancements of AI-precision medicine in the gastroenterology field and the importance of early and accurate preventative care. Iterative Scopes is increasing the accuracy of colonoscopies with its computer-aided detection tool, SKOUT™. SKOUT assists qualified and trained gastroenterologists in identifying potential colorectal polyps during colonoscopy examinations in adult patients undergoing colorectal cancer screening, but does not replace physician judgement or diagnosis. SKOUT has received FDA 510(k) clearance for its AI-assisted polyp detection device for adult colorectal cancer screenings or surveillance. Visit: www.iterativescopes.com to learn more.

Dr. Sarah Ringold, MD, MS, Director of Clinical Research in Pediatric Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson discusses the US FDA approval of STELARA ® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). Healthcare providers now have access to a first-in-class treatment option – with an established track record of safety and efficacy – for this rare disease that affects five to eight percent of children and adolescents with chronic inflammatory arthritis.

Dr. Clayton Lau, chief, Division of Urology and Urologic Oncology at City of Hope, a leading-edge cancer research and treatment organization, discusses how prostate-specific membrane antigen (PSMA) PET scans significantly improve prostate cancer detection and treatment. He talks about single-port robotic prostatectomy that improves recovery time and how prostate surgery is increasingly becoming an outpatient procedure with same-day discharge.

​Dr. Maria Ryan, DDS, PhD, ​Vice President and Chief Clinical Officer at the Colgate-Palmolive Company discusses the link between oral health, heart disease and stroke as well as other health complications. She talks about why women have special oral health requirements as well as what they can do to protect and improve their overall health by focusing on oral health.

Dr. Arthur Suckow, CEO of DTx Pharma, a San Diego-based biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of rare diseases, discusses the current challenges with RNA therapeutics and the development of a platform called FALCON™ (Fatty Acid Ligand Conjugated OligoNucleotide).

Returning guest, Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, a veteran of the industry and a developer of novel therapies that target various phases of cell cycle control for the treatment of cancer, shares an update on the dose escalation study of Fadraciclib in solid and blood cancers.